Mrs Sarah Lynne Horrocks, | |
21 Glen Ave, Chelmsford, MA 01824-2858 | |
(978) 256-0667 | |
(978) 453-6767 |
Full Name | Mrs Sarah Lynne Horrocks |
---|---|
Gender | Female |
Speciality | Marriage & Family Therapist |
Location | 21 Glen Ave, Chelmsford, Massachusetts |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1972663540 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
106H00000X | Marriage & Family Therapist | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Sarah Lynne Horrocks, 21 Glen Ave, Chelmsford, MA 01824-2858 Ph: (978) 256-0667 | Mrs Sarah Lynne Horrocks, 21 Glen Ave, Chelmsford, MA 01824-2858 Ph: (978) 256-0667 |
News Archive
In a paper recently published in the Nature journal Scientific Reports, a retrospective cohort study on inflammatory biomarkers in pregnant women with COVID-19 reveals key differences that could better allow an accurate COVID-19 prognosis to be attained in pregnant women.
ChemoCentryx, Inc., today announced that GlaxoSmithKline (GSK) has exercised its option to obtain an exclusive license for further development and worldwide commercialization of the investigational medicine CCX354, a potent and selective inhibitor of CCR1, a chemokine receptor that drives the recruitment of inflammatory cells into the joints of patients with rheumatoid arthritis (RA).
Just 5 percent of Parkinson's disease cases can be explained by genetic mutation, while the rest have no known cause. But a new discovery by researchers at The University of Texas Health Science Center San Antonio may begin to explain why the vast majority of Parkinson's patients develop the progressive neurodegenerative disease.
A team led by researchers at Albert Einstein College of Medicine of Yeshiva University has found a clear link between living to 100 and inheriting a hyperactive version of an enzyme that rebuilds telomeres - the tip ends of chromosomes. The findings appear in the latest issue of the Proceedings of the National Academy of Sciences.
Genta Incorporated today announced that tesetaxel, the leading oral taxane in clinical development, has been designated as an Orphan Drug by the European Medicines Agency for gastric cancer. The drug has previously received Orphan Drug designation by the U.S. Food and Drug Administration for both gastric cancer and melanoma, as well as Fast Track designation by FDA for gastric cancer.
› Verified 2 days ago
Patrick Atenyi Ssekyole, Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 6 Boston Rd Ste 201, Chelmsford, MA 01824 Phone: 978-677-6354 | |
Robin A Risso, LMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 21 Glen Ave, Chelmsford, MA 01824 Phone: 978-256-0667 Fax: 978-256-5567 |